Please Wait.....
Report
Italy Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 100 Pages I Mordor Intelligence
Italy Diabetes Devices Market Analysis
Italy diabetes devices market stood at USD 1.1 billion in 2025 and is forecast to reach USD 1.52 billion by 2030, advancing at a 6.7% CAGR. The steady rise reflects an aging population, a 92.14% dominance of Type 2 cases, and a policy environment that reimburses continuous glucose monitoring (CGM) for priority groups under the National Health Service. Adoption accelerates further as pharmacies become clinical hubs, telemedicine tools spread to 72% of facilities, and hybrid closed-loop pumps enter reimbursement formularies. Management products enjoy a 7.14% CAGR due to weekly insulin and tubeless automated delivery roll-outs, while monitoring devices retain scale leadership at 58.12% share in 2024. North-South funding gaps and stringent European accuracy rules temper momentum, yet targeted digital spending of EUR 1.6 billion keeps Italy among Europe's most attractive pilots for advanced diabetes technology.
Italy Diabetes Devices Market Trends and Insights
Reimbursement of CGM Sensors for T1 & Pediatric Patients
Parliamentary Law 130/2023 mandates national screening for citizens aged 1-17 years, routing newly diagnosed children swiftly toward CGM adoption . The Ministry of Health already funds FreeStyle Libre for both Type 1 and insulin-intensive Type 2 users, removing a key cost hurdle. Multi-center trials in Lombardy, Emilia Romagna, and Toscana report HbA1c falls of 0.4% at three months and 0.6% at six months with intermittently scanned CGM. Early CGM habituation in childhood is expected to lift lifetime adherence and enlarge long-term sensor revenue. Implementation lags occur in Calabria and Sardegna, yet national reimbursement rules give suppliers a clear demand signal.
Growing Telemedicine Adoption & Home-Care Push Post-PNRR
EUR 1.6 billion from the Recovery Plan modernizes electronic health records, enabling 72% of hospitals to activate tele-consults that directly feed glucose data into clinical portals. Surveys of 600 clinicians show 82% endorse tele-follow-up for routine glycemic reviews, while 80% cite infection-control gains in a post-COVID era. The Connected Care platform and Resilia app allow secure sharing of sensor feeds, though 66% of practitioners caution that digital care cannot replace critical in-person titration visits. Broadband blackspots in inland Basilicata slow real-time uploads, but pharmacy Wi-Fi stations increasingly bridge the gap. Overall, remote monitoring saves travel time for elderly patients and encourages continuous data flow that underpins closed-loop dosing algorithms.
Regional Funding Disparity Between North & South
Seven regions, including Calabria and Sardegna, failed minimum-care benchmarks in 2021, leading to rationed CGM allocations and longer waiting lists. New autonomy legislation of June 2024 allows wealthier regions to self-fund enhanced benefits, potentially widening access gaps. Out-of-pocket drug spending equals 23% of national healthcare costs but weighs heavier on lower-income households prevalent in the South. Clinician migration northward compounds capacity shortages. Device suppliers must therefore calibrate pricing tiers and co-pay support programs to avoid lost volumes in underfunded territories.
Other drivers and restraints analyzed in the detailed report include:
Expansion of Pharmacy-Run Diabetes Clinics / Rising Prevalence & Earlier Onset of Type 2 Diabetes / Strict eCGM Accuracy Rules Delaying New Entrants /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
The monitoring category retained 58.12% of Italy diabetes devices market share in 2024, underpinned by the country's entrenched self-testing culture and full reimbursement of FreeStyle Libre for intensive insulin users. Italy diabetes devices market size for monitoring solutions was USD 0.64 billion in 2025 and is set to climb at a 5.9% CAGR on the strength of sensor upgrades and wider pediatric coverage. Blood-glucose strips continue to sell because many seniors trust finger-prick verification, yet Libre 2 users showed HbA1c drops of 0.6% after six months in a 2,000-patient Lombardy cohort . Hospitals increasingly deploy professional CGM for in-patient titration, expanding the addressable volume of disposable sensors.
Management devices, valued at USD 0.46 billion in 2025, outpace monitoring with a 7.14% CAGR to 2030 as automated delivery platforms proliferate. Insulet's Omnipod 5 launch in January 2025 introduced the first tubeless system with dual-sensor compatibility, extending choice for the 300,000 Italian Type 1 users eligible for public reimbursement. The weekly insulin Icodec debut in June 2025 slashes injection events by 86%, triggering needle-syringe replacement cycles and encouraging pump trials for dose accuracy. Italian comparative studies reveal MiniMed 780G achieves 71% Time-in-Range, exceeding Tandem Control-IQ's 68% result, influencing endocrinologist prescribing behaviour. Pen-needle makers follow SIMDO guidance favoring 4 mm 32G formats to minimize lipohypertrophy risk. Management innovations thereby cement a higher-growth runway within the Italy diabetes devices market.
The Italy Diabetes Devices Market Report Segments the Industry Into Device Type (Management Devices and Monitoring Devices), End User (Hospital & Clinics, Home-Care Settings, and More), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational & Other Specific Types). The Market Sizes and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Abbott Laboratories / Roche / Lifescan / Dexcom / Medtronic / Arkray / Ascensia / Novo Nordisk / Eli Lilly and Company / Sanofi / Insulet / A. Menarini Diagnostics / Sinocare / Terumo / B. Braun / Ypsomed / Tandem Diabetes Care /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Reimbursement of CGM sensors for T1 & pediatric patients
4.2.2 Growing telemedicine adoption & home-care push post-PNRR
4.2.3 Expansion of pharmacy-run diabetes clinics (Farmacie dei Servizi)
4.2.4 Rising Prevalence of Obesity Among Youth Increasing Earlier Onset Diabetes
4.2.5 AI-powered decision-support in hybrid-closed-loop pumps
4.2.6 Rising prevalence & earlier onset of Type-2 diabetes
4.3 Market Restraints
4.3.1 Regional funding disparity between North & South
4.3.2 Strict eCGM accuracy rules delaying new entrants
4.3.3 Supply-chain exposure to single-use plastics legislation
4.3.4 Data-privacy constraints on cloud glucose platforms
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Device Type
5.1.1 Management Devices
5.1.1.1 Insulin Pump
5.1.1.1.1 Insulin Pump Device
5.1.1.1.2 Insulin Pump Reservoir
5.1.1.1.3 Infusion Set
5.1.1.2 Insulin Syringes
5.1.1.3 Cartridges in Reusable Pens
5.1.1.4 Insulin Disposable Pens
5.1.1.5 Jet Injectors
5.1.2 Monitoring Devices
5.1.2.1 Self-Monitoring Blood Glucose
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Blood Glucose Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Continuous Glucose Monitoring
5.1.2.2.1 Sensors
5.1.2.2.2 Durables
5.2 By End User
5.2.1 Hospitals & Clinics
5.2.2 Home-care Settings
5.2.3 Specialized Diabetes Centers & Pharmacies
5.3 By Patient Type
5.3.1 Type-1 Diabetes
5.3.2 Type-2 Diabetes
5.3.3 Gestational & Other Specific Types
6 Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7 Competitive Landscape
7.1 Market Concentration
7.2 Market Share Analysis
7.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, and Recent Developments)
7.3.1 Abbott Diabetes Care
7.3.2 Roche Diabetes Care
7.3.3 LifeScan Inc.
7.3.4 Dexcom
7.3.5 Medtronic
7.3.6 Arkray Inc.
7.3.7 Ascensia Diabetes Care
7.3.8 Novo Nordisk A/S
7.3.9 Eli Lilly
7.3.10 Sanofi
7.3.11 Insulet Corporation
7.3.12 A. Menarini Diagnostics
7.3.13 Sinocare Inc.
7.3.14 Terumo Corporation
7.3.15 B. Braun Melsungen AG
7.3.16 Ypsomed AG
7.3.17 Tandem Diabetes Care
8 Market Opportunities & Future Outlook
8.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security